Method for the management of incontinence
AssigneeAlza Corporation
InventorsGeorge V. Guittard, Francisco Jao, Susan M. Marks, David J. Kidney, Fernando E. Gumucio
Life of this patent
Estimating the term…
Abstract
A composition and a dosage form are disclosed comprising oxybutynin alone/or accompanied by another drug indicated for therapy. A method is disclosed for administering oxybutynin alone/or accompanied by a different drug or for administering oxybutynin and a different drug according to a therapeutic program for the management of incontinence alone, and for other therapy.
Claims31
A method for the management of incontinence in a patient, wherein the method comprises admitting orally into the patient a dosage form comprising 240 ng to 650 mg a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, that is administered once-a-day at a release rate of 0.05 mg per hour up to 0.850 mg per hour for the management of incontinence in the patient.
A method for treating incontinence in a patient exhibiting the symptoms of incontinence, wherein the method comprises admitting orally into the patient a sustained release dosage form comprising 240 ng to 650 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt that is administered once-a-day at a incontinence-managing rate of 10 ng per hour to 20 mg per hour for the management of incontinence.
A method for the management of incontinence and for the management of hormone replacement therapy in a patient, wherein the method comprises administering once-a-day a sustained-release therapeutically effective dose of a member selected from the group consisting oxybutynin and its pharmaceutically acceptable salt for the management of incontinence, and administering a therapeutically effective dose of an estrogenic steroid for the management of hormone replacement therapy to the patient in need of both therapies.
A method for treating involuntary incontinence in a patient, wherein the method comprises admitting orally into the patient a sustained release once-a-day dosage form comprising 240 ng to 650 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, that is administered in a sustained rate to provide in the plasma of the patient a higher oxybutynin/desethylmetabolite ratio than about 0.18 to 1 for treating involuntary incontinence in the patient.
A method for managing the concentrations of oxybutynin (OXY) and its desethylmetabolite (DESOXY) in the plasma of a patient, and for managing incontinence in the patient, wherein the method comprises admitting orally into the patient a once-a-day dosage form comprising 240 ng to 650 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, that is administered at a controlled rate to provide higher OXY/DESOXY ratio than about 0.18 to 1 for managing the plasma concentrations and for managing incontinence in the patient.
A method for the management of overactive bladder and for increasing compliance in a patient in need of said management and compliance wherein the method comprises admitting orally into the patient a once-a-day dosage form comprising 240 ng to 650 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt that is administered in a sustained-release dosage of 0.10 ng per hour to 25 mg per hour for increasing patient compliance for the management of overactive bladder in the patient.
A method for treating an overactive bladder in a female patient, wherein the method comprises admitting orally once-a-day into the patient a dosage form comprising 240 ng to 650 mg a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt that is administered once-a-day in a controlled release dose of 0.05 mg per hour to 0.850 mg per hour for treating the overactive bladder in the female patient.
The method for the management of overactive bladder and hormone replacement therapy in a female patient, wherein the method comprises orally administering once-a-day to the patient a member selected from a group consisting of oxybutynin and its pharmaceutically acceptable salt at a therapeutically-effective, sustained release rate for the management of the overactive bladder, and orally administering to the patient a composition comprising a therapeutically-effective amount of a steroid selected from the group an estrogen and a progestin for hormone replacement therapy.
Dependencies are inferred from the claim text.